3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Keratosis, Actinic
2
Pituitary Neoplasms
1
Pain
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lung Neoplasms
1
Hemorrhage
1
Haloperidol
1
Growth Hormone-Secreting Pituitary Adenoma
1
Brain Neoplasms
1
Anemia
1
Acromegaly
1
Interventions
Radiotherapy
8
Zoledronic Acid
7
Fentanyl
7
nabiximols
6
Morphine
6
Ibandronic Acid
6
Ketamine
5
Hydromorphone
5
Analgesia
5
Acetaminophen
5
Tapentadol
4
Oxycodone
4
Acupuncture Therapy
4
alvimopan
3
Ropivacaine
3
Prednisone
3
Lidocaine
3
cabozantinib
2
Tetrodotoxin
2
Mitoxantrone
2
Gabapentin
2
Duloxetine Hydrochloride
2
Docetaxel
2
Calcium
2
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
2
strontium chloride
1
resiniferatoxin
1
oxycodone-acetaminophen
1
oxycodone naloxone combination
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pain
×
Solutions
×
Clear all
NCT01836328
2016-03-16
RATIOMTD
L'Hospitalet de Llobregat
Phase 3
Completed
44 enrolled